PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 150
- Registration Number
- NCT05926960
- Locations
- 🇮🇹
Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
🇮🇹Istituto Europeo di Oncologia IRCCS, Milano, Italy
🇸🇰Nemocnica Poprad, a.s., Poprad, Slovakia
BESPONSA Injection 1 mg Special Investigation
- Conditions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 421
- Registration Number
- NCT05923112
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults
- Conditions
- Interventions
- Drug: Single dose of PF-07220060 as first Tablet FormulationDrug: Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administrationDrug: Single dose of PF-07220060 as third tablet formulationDrug: Single dose of PF-07220060 as second Tablet FormulationDrug: Single dose of PF-07220060 as a Tablet Formulation
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 113
- Registration Number
- NCT05923411
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)
- Conditions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1300
- Registration Number
- NCT05912933
A Study of Vepdegestrant (ARV-471, PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1180
- Registration Number
- NCT05909397
- Locations
- 🇺🇸
Lakeland Regional Cancer Center, Lakeland, Florida, United States
🇺🇸Radiology and Imaging Specialists, Lakeland, Florida, United States
🇺🇸Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT05907395
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05905341
A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin
- Conditions
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05898672
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 128
- Registration Number
- NCT05900154
- Locations
- 🇺🇸
Velocity Clinical Research, Salt Lake City, West Jordan, Utah, United States
🇺🇸Seattle Children's - Building Cure, Seattle, Washington, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT05896163
- Locations
- 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇺🇸The University of Kansas Cancer Center ,Investigational Drug Services, Fairway, Kansas, United States
🇺🇸The University of Kansas Clinical Research Center, Fairway, Kansas, United States